Table 1 Ongoing clinical trials evaluating gallbladder cancer (GBC)
From: Overview of current targeted therapy in gallbladder cancer
Drug investigated | Molecular target | Target population | Phase | Clinical trail ID | Locations |
|---|---|---|---|---|---|
Sorafenib | Multitargeted TKI | GBC | 2 | NCT00238212 | USA |
Sorafenib | Multitargeted TKI | Extrahepatic bile duct cancer, GBC | 2 | NCT00919061 | USA |
Sorafenib | Multitargeted TKI | BTC | 1 and 2 | NCT00955721 | USA |
Sorafenib | Multitargeted TKI | GBC | 3 | NCT01053390 | China |
KBP-5209 | Multitargeted TKI | Solid tumors | 1 | NCT02442414 | USA |
Erlotinib | EGFR | Solid tumors | 1 | NCT00397384 | USA |
Bevacizumab | EGFR, VEGFR | Upper gastrointestinal cancers | 2 | NCT00350753 | Denmark |
Bevacizumab | EGFR, VEGFR | BTC | 2 | NCT00356889 | USA |
Bevacizumab | EGFR, VEGFR | BTC | 2 | NCT00361231 | USA |
Bevacizumab | EGFR, VEGFR | BTC | 2 | NCT01007552 | USA |
Afatinib | EGFR, HER2 | GBC | 2 | NCT04183712 | China |
Apatinib | EGFR, HER2 | GBC | 2 | NCT03702491 | China |
Lapatinib | HER2 | BTC | 2 | NCT00101036 | USA |
Lapatinib | HER2 | BTC | 2 | NCT00107536 | USA |
Trastuzumab, R115777 | HER2 | Solid tumors | 1 | NCT00005842 | USA |
Trastuzumab | HER2 | Advanced or metastatic GBC | 2 | NCT00478140 | USA |
Trastuzumab, IL-12 | HER2, IL-12 | Solid tumors | 1 | NCT00004074 | USA |
IL-2 | HER2 | Solid tumors | 1 | NCT02662348 | China |
Cediranib | VEGFR | BTC | 2 | NCT01229111 | USA |
Ramucirumab | VEGFR2 | BTC | 2 | NCT02520141 | USA |
Ramucirumab, merestinib | VEGFR2, c-MET | BTC | 2 | NCT02711553 | USA |
Pazopanib | VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, c-Fms | BTC | 2 | NCT01855724 | Greece |
Vandetanib | VEGFR2–3, EGFR, RET | Advanced BTC | 2 | NCT00753675 | Italy |
Regorafenib | VEGFR1–3, PDGFRβ, KIT, RET Raf-1 | BTC | 2 | NCT02115542 | USA |
Regorafenib | VEGFR1–3, PDGFRβ, KIT, RET Raf-2 | BTC | 2 | NCT02053376 | USA |
Panitumumab | Kras, BRAF | BTC | 2 | NCT01308840 | USA |
Selumetinib | MEK | BTC | 1 | NCT01242605 | United Kingdom |
Selumetinib | MEK | BTC | 2 | NCT02151084 | Canada |
Atezolizumab | MEK | BTC | 2 | NCT03201458 | USA |
Trametinib | MEK | BTC or GBC | 2 | NCT02042443 | USA |
Trametinib | MEK | BTC | 2 | NCT01943864 | Japan |
ARRY-438162 | MEK | Solid tumors | 1 | NCT00959127 | USA |
GSK1120212 | MEK | Solid tumors | 1 | NCT01324258 | Japan |
MEK162 | MEK | BTC | 1 | NCT02105350 | USA |
MEK162 | MEK | BTC | 1 and 2 | NCT01828034 | USA |
MEK162 | MEK | BTC | 1 and 2 | NCT02773459 | Korea |
Everolimus | mTOR | Solid tumors | 1 | NCT00949949 | USA |
Nivolumab | PD-1 | BTC | 2 | NCT02829918 | USA |
Nivolumab | PD-1 | BTC | 2 | NCT03101566 | USA |
Pembrolizumab | PD-1 | BTC | 2 | NCT03260712 | Spain |
Pembrolizumab | PD-1 | BTC | 2 | NCT03111732 | USA |
Pembrolizumab | PD-1 | BTC | 3 | NCT04003636 | USA |
M7824 | PD-1 | BTC | 2 | NCT03833661 | USA |
Toripalimab + lenvatinib | PD-1 | BTC | 2 | NCT04211168 | China |
Nivolumab, ipilimumab | PD-1, CTLA-4 | Solid tumors | 2 | NCT02834013 | USA |
STI-3031 | PD-L1 | BTC | 2 | NCT03999658 | USA |
Avelumab | PD-L1 | Solid tumors | 1 and 2 | NCT04068194 | USA |
Durvalumab | PD-L1 | BTC | 2 | NCT04308174 | Korea |
Durvalumab/tremelimumab | PD-L1, CTLA-4 | BTC | 2 | NCT03473574 | Germany |
Intrafusp alfa | PD-L1, TGF-β | BTC | 2 and 3 | NCT04066491 | USA |
Selumetinib | AKT | BTC | 2 | NCT01859182 | USA |
MK-2206 | AKT | BTC | 2 | NCT01425879 | USA |
IL-12 | IL-12 | Solid tumors | 1 | NCT00003046 | USA |
IL-12 | IL-12 | Solid tumors | 1 | NCT00003439 | USA |
Guadecitabine | DNMT | Advanced liver, pancreatic, BTC, GBC | 1 | NCT03257761 | USA |
CEA RNA-pulsed DC cancer vaccine | CEA | Solid tumors | 1 | NCT00004604 | USA |
EphB4-HSA fusion protein | EphB4, HSA | Solid tumors | 1 | NCT02495896 | USA |
ADH-1 | N-cadherin | Solid tumors | 1 | NCT01825603 | USA |
CPI-613 | PDH, α-KGDH | BTC | 1 and 2 | NCT04203160 | USA |
Glivec | ABL, KIT, PDGFR | BTC | 2 | NCT01153750 | Germany |
DKN-01 | DKK1 | BTC | 1 | NCT02375880 | USA |
PSMA/PRAME | T cells | Solid tumors | 1 | NCT00423254 | USA |
Merestinib | MET | Solid tumors | 1 | NCT03027284 | Japan |
FT-2102 | IDH1 | Solid tumors | 1 and 2 | NCT03684811 | USA |
Entinostat | HDAC | Solid tumors | 1 | NCT00020579 | USA |
CGX1321 | PORCN | Solid tumors | 1 | NCT03507998 | China |
Ceralasertib | PARP | Solid tumors | 2 | NCT03878095 | USA |
